Ebola virus vaccine - Auro Vaccines
Latest Information Update: 10 Mar 2024
At a glance
- Originator Auro Vaccines
- Developer Auro Vaccines; Emergent BioSolutions
- Class Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Ebola virus infections
Most Recent Events
- 19 Feb 2024 Auro Vaccines files patent for VesiculoVax™ platform (Auro Vaccines pipeline, February 2024)
- 19 Feb 2024 Phase-I clinical trials in Ebola virus infections (Prevention) (unspecified route) (Auro Vaccines pipeline, February 2024)
- 19 Feb 2024 Preclinical trials in Ebola virus infections (Prevention) in USA (unspecified route) (Auro Vaccines pipeline, February 2024)